flanders.bio is the cluster organisation empowering a life sciences driven network economy

We are a dynamic member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.

News from flanders.bio and its members

CMAST is stepping into a strategic partnership with FlandersBio as of April 1st, 2017

CMAST is stepping into a strategic partnership with FlandersBio as of April 1st, 2017.
Through this partnership with FlandersBio, CMAST underlines its engagement of enabling Life Science Innovation in general and in Flanders in particular.

| 31 March 17 Read more

Promethera Biosciences Presents Preclinical Data on Novel H2Stem Cell Therapy at EASL International Liver Congress

Promethera Biosciences SA, a global innovator in cell-based medicines, today presented novel in vitro and in vivo data on its preclinical pipeline program H2Stem at the European Association for the Study of the Liver (EASL) International Liver Congress 2017 in Amsterdam, The Netherlands. The poster presentation highlighted H2Stem’s therapeutic potential as a valuable addition to Promethera’s pipeline in liver-directed cell therapies.

Biocartis Group NV: Disclosure of a transparency notification

Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the 'Belgian Transparency Act'), that it received a transparency notification dated 19 April 2017 (the 'Notification'), indicating that as a result of the acquisition of voting securities on 19 April 2017, Sycomore Asset Management now holds 5.15% of the voting rights in Biocartis. As a result, it has crossed the notification threshold of 5%.

ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema

ThromboGenics, a biotechnology company focusing on novel treatments for back of the eye disease and diabetic eye disease, announced it has achieved an important milestone in the advancing of the pre-clinical development of its THR-149, a novel plasma kallikrein inhibitor, which the company is developing for the treatment of Diabetic Macular Edema (DME). 

Ablynx announces warrant exercise

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 57,125 common shares have been issued by the Company in exchange for €398,801.77 as the result of the exercise of warrants.

flanders.bio events

Alternate Text

17/05/2017 - State of the Union 2017

The evening before the annual Knowledge for Growth Conference we are organising the 3rd edition of our State of the Union; a moment to announce new developments and initiatives in the Flemish life sciences cluster and how we position ourselves vis-a-vis the European landscape. After several inspiring talks, there will be plenty of networking opportunities, accompanied by fine food and drinks. 

Strategic Partners